Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

Brian I. Rini, MD
Published: Thursday, May 23, 2019



Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with metastatic renal cell carcinoma (mRCC).

Combining 2 drugs will typically result in more toxic than a monotherapy, especially if it is 2 different classes of drugs. Fortunately, Rini notes, the PD-1 inhibitor pembrolizumab and the VEGF TKI axitinib are fairly well tolerated on their own. Axitinib is one of the better tolerated TKIs, with diarrhea, fatigue, and high blood pressure among the most common side effects. Pembrolizumab is associated with immune-related adverse events, but it is generally a tolerable agent.

In the phase III KEYNOTE-426 trial, the combination resulted in expected toxicities, Rini says. When one looks at the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo), for example, there is a lot of inflammatory toxicity upfront. With pembrolizumab plus axitinib, the side effects are more drawn out. In April 2019, the FDA approved pembrolizumab plus axitinib for the frontline treatment of patients with mRCC based on the results of the KEYNOTE-426 trial.
SELECTED
LANGUAGE


Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with metastatic renal cell carcinoma (mRCC).

Combining 2 drugs will typically result in more toxic than a monotherapy, especially if it is 2 different classes of drugs. Fortunately, Rini notes, the PD-1 inhibitor pembrolizumab and the VEGF TKI axitinib are fairly well tolerated on their own. Axitinib is one of the better tolerated TKIs, with diarrhea, fatigue, and high blood pressure among the most common side effects. Pembrolizumab is associated with immune-related adverse events, but it is generally a tolerable agent.

In the phase III KEYNOTE-426 trial, the combination resulted in expected toxicities, Rini says. When one looks at the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo), for example, there is a lot of inflammatory toxicity upfront. With pembrolizumab plus axitinib, the side effects are more drawn out. In April 2019, the FDA approved pembrolizumab plus axitinib for the frontline treatment of patients with mRCC based on the results of the KEYNOTE-426 trial.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x